Neurovance (Cambridge, MA), a clinical-stage pharmaceutical company focused on treatments for CNS disorders such as adult attention deficit hyperactivity disorder, closed a $7M Series A financing. Participants include Novartis Venture Fund.

Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem

Request Collective IP Account Access HERE